In addition, a number of articles reported the relationship between polymorphisms and LN treatment, including efficacy and side effects,[19,20] and drug interactions.[21] However, few studies have reported that MCP-1-2518 A/G polymorphism is involved in the therapeutic implications of LN. Here, CCL2 is linked to lobular neoplasia.